Haesook Kim

Principal Research Scientist
This email address is being protected from spambots. You need JavaScript enabled to view it.



Our major research activities involve the design, conduct and analysis of translational clinical trials, animal and laboratory studies that arise from adult hematopoietic stem cell transplantation (HSCT) projects and cancer vaccine studies at DF/HCC, as well as translational laboratory studies of leukemia outside of DF/HCC. Our major statistical interests include the design of clinical trials, analysis of competing risks data, analysis of time-to-event data, analysis of longitudinal data, and analysis of SNP and gene array data.

Allogeneic hematopoietic stem cell transplantation (HSCT) is the transplantation of stem cells derived from the bone marrow or blood. The therapeutic benefit and potential cure achieved by HSCT is mediated by the graft-vs-tumor effect. The conventional HSCT has used high doses of chemotherapy and/or total body irradiation for both eradication of underlying malignancies and suppression of the host's immune system to allow donor engraftment. However, the conventional HSCT has an impact on the increased tissue damage and intensified inflammatory state in the host, leading to significant transplant-related mortalities and morbidities. Reduced intensity conditioning regimens (RIC) use less intense conditioning regimens and rely on the adoptively transferred donor's immune cells for the eradication of host malignancies. Thus, RIC has opened the possibility of HSCT for the elderly and for patients with comorbid conditions who would otherwise be ineligible for conventional HSCT. Unfortunately, RIC is associated with an increased risk of disease recurrence, indicating that the immunologic effects of these two types of transplant on disease recurrence and transplant-related mortality are different.


Competing risks data are inherent in HSCT studies since the immunologic mechanisms of disease recurrence and transplant-related mortality are interdependent, and efforts have been made to reduce transplant related mortality (RIC) but at the cost of increased risk of disease recurrence. Thus, when competing risks are present, standard time-to-event analysis censoring competing risks leads to biased results. Instead, competing risks data analysis should be performed.



Dr. Kim received her PhD in 1994 from the University of North Carolina at Chapel Hill, and then worked for the National Institute of Child Health and Human Development. Later she was an Assistant professor at the University of Pittsburgh, and in 1999, joined DFCI, where she has served as a statistician for leukemia, allogeneic stem cell transplantation, cancer vaccine studies, and studies of human cell therapies. Her research focuses on statistical issues of designing clinical trials and analysis of competing risks data, time-to-event data, and SNP and gene array data with special emphasis on stem cell transplantation and cancer vaccine studies.


Recent Publications

Kekre N, Kim HT, Ho VT, Cutler C, Armand P, Nikiforow S, Alyea EP, Soiffer RJ,
Antin JH, Connors JM, Koreth J. Venous thromboembolism is associated with
graft-versus-host disease and increased non-relapse mortality after allogeneic
hematopoietic stem cell transplantation. Haematologica. 2017 Mar 24. pii:


Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, Sando Y, Yagita
H, Koreth J, Kim HT, Alyea EP, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ,
Maeda Y, Tanimoto M, Ritz J, Matsuoka KI. PD-1 modulates regulatory T-cell
homeostasis during low-dose interleukin-2 therapy. Blood. 2017 Apr


Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA,
Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescaut W,
Thiebaut-Bertrand A, François S, Stamatoullas-Bastard A, Rohrlich PS, Labussière Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand P. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017 Mar 9;129(10):1380-1388.


Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V,
Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan;35(1):24-31.


Brunstein CG, Cutler CS, DeFor TE, Kim H, Bejanyan N, Garfall A, Verneris MR,
Chen YB, Warlick ED, Spitzer T, Miller JS, Antin JH, Weisdorf DJ, Soiffer R,
Wagner JE, Ballen KK. Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. Biol Blood Marrow Transplant. 2017 Jan;23(1):126-133.


Hirakawa M, Matos TR, Liu H, Koreth J, Kim HT, Paul NE, Murase K, Whangbo J,
Alho AC, Nikiforow S, Cutler C, Ho VT, Armand P, Alyea EP, Antin JH, Blazar BR,
Lacerda JF, Soiffer RJ, Ritz J. Low-dose IL-2 selectively activates subsets of
CD4(+) Tregs and NK cells. JCI Insight. 2016 Nov 3;1(18):e89278.


Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, Alyea EP, Carlton VE,
Chen YB, Cutler CS, Ho VT, Koreth J, Kotwaliwale C, Nikiforow S, Ritz J, Rodig
SJ, Soiffer RJ, Antin JH, Armand P. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016 Dec;175(5):841-850.


Treister N, Li S, Kim H, Lerman M, Sultan A, Alyea EP, Armand P, Cutler C, Ho
V, Koreth J, Antin JH, Soiffer R. An Open-Label Phase II Randomized Trial of
Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2016


Xiang M, Kim H, Ho VT, Walker SR, Bar-Natan M, Anahtar M, Liu S, Toniolo PA,
Kroll Y, Jones N, Giaccone ZT, Heppler LN, Ye DQ, Marineau JJ, Shaw D, Bradner
JE, Blonquist T, Neuberg D, Hetz C, Stone RM, Soiffer RJ, Frank DA. Gene
expression-based discovery of atovaquone as a STAT3 inhibitor and anti-cancer
agent. Blood. 2016 Aug 16.


Yu L, Kim HT, Kasar SN, Benien P, Du W, Hoang K, Aw A, Tesar B, Improgo R,
Fernandes SM, Radhakrishnan S, Klitgaard JL, Lee C, Getz G, Setlur SR, Brown JR. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Clin Cancer Res. 2017 Feb 1;23(3):735-745.


Related Links